Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Cynthia Planeaux

Nurse Practitioner Taylor Mill, KY Nurse Practitioner

NPI 1972569283 CMS profile 10688346

5100 Peace Way, Taylor Mill, KY 41015

Open in the dashboard

General payments

$11,040

389 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cynthia Planeaux of Taylor Mill, KY is reported in the CMS Open Payments database as having received $11,040 across 389 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,163 91
2024 General $2,251 84
2023 General $2,438 86
2022 General $1,432 57
2021 General $1,756 71

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cynthia Planeaux
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Cynthia Planeaux were reported at $3,163. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Cynthia Planeaux Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,756 $135 $40–$426 $132
2022 $1,432 $152 $48–$470 $149
2023 $2,438 $166 $54–$529 $160
2024 $2,251 $173 $55–$556 $164
2025 $3,163 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,315 88 payments
  2. AstraZeneca Pharmaceuticals LP $1,847 27 payments
  3. Novo Nordisk Inc $1,061 47 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $744 23 payments
  5. Lilly USA, LLC $585 24 payments
  6. GlaxoSmithKline, LLC. $453 22 payments
  7. Axsome Therapeutics, Inc. $417 8 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $354 25 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $327 14 payments
  10. Pfizer Inc. $259 17 payments
  11. Other $2,679 94 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,040 389 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $868 37 payments
  2. Kerendia $744 23 payments
  3. Wegovy $634 22 payments
  4. FARXIGA $632 15 payments
  5. BREZTRI $608 6 payments
  6. VRAYLAR Neuroscience $587 27 payments
  7. QULIPTA $437 22 payments
  8. AIRSUPRA $373 4 payments
  9. VRAYLAR Neuroscience $368 8 payments
  10. XIFAXAN $354 25 payments
  11. Other $6,634 277 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 118 drugs

Part D claims

6,341

Median for Nurse Practitioner: 389

Drug cost

$631,960

Median for Nurse Practitioner: $21,885

Branded share of claims

21.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 62 $103,435
Farxiga Dapagliflozin Propanediol Brand 66 $78,978
Eliquis Apixaban Brand 56 $74,654
Jardiance Empagliflozin Brand 66 $72,363
Mounjaro Tirzepatide Brand 30 $53,021
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 51 $51,264
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 40 $43,952
Linzess Linaclotide Brand 25 $28,804
Myrbetriq Mirabegron Brand 36 $25,829
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 20 $11,537

The 10 drugs with the highest cost, of 118 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$34,764

Of which drugs: $10,329

Medicare patients

203

Average age 71

Services billed

1,130

130 women, 73 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 50%
Depression 33%
Diabetes 32%
Ischemic heart disease 31%
Chronic kidney disease 31%
COPD 25%
Osteoporosis 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 53 58 $4,657
Sarscv2 vac 30mcg trs-suc im 91320 Office 20 22 $3,240

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $220
$220 — —
Wegovy
  • Novo Nordisk Inc $201
$201 — —
GVOKE HYPOPEN
  • Xeris Pharmaceuticals, Inc. $153
$153 — —
ZEPBOUND
  • Lilly USA, LLC $138
$138 — —
Auvelity
  • Axsome Therapeutics, Inc. $126
$126 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

389 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record